ERBB2 and breast cancer: Furthermore, HER2-DC1 i.t. combined with anti-HER2 antibodies treatment effectively attenuated the growth of untreated distant HER2pos tumors, highlighting its potential in generating systemic antitumor immunity in HER2pos BC.